Amgen, Inc. vs Avient Corporation — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Avient Corporation trades at $45.2 (market cap $4.17B). The key difference: Amgen, Inc. is far larger — about 53.8× Avient Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | AVNT | |
|---|---|---|
Market Cap | $224.14B | $4.17B |
Sector | Health | Technology |
52-Week High | $417.20 | $45.69 |
52-Week Low | $271.18 | $27.48 |
Enterprise Value | $267.45B | $5.62B |
Dividend Yield | 2.43% | 2.42% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
AVNT trades at $45.33, down 0.7% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and raised full-year guidance. Revenue growth of 5.8% to $917 million reflects robust demand and operational efficiency. Analysts maintain a buy consensus with a $49.00 price target, citing momentum and value metrics.
Outlook is positive due to consistent earnings beats and dividend payments, but risks include high valuation (P/E 24.55) and potential margin pressure from input costs. Investors should monitor Q3 2026 results against the $0.79 EPS estimate for sustained growth confirmation.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →